Chapter 18 Summary
Chapter 18 Summary
An initiator caspase containsa protease domain in its carboxyterminal region, and a small protein interaction domain near its
amino terminus. It is initially made in an inactive, monomeric form
(procaspase). Apoptotic signals trigger the assembly of adaptor
proteins carrying multiple binding sites for the caspase aminoterminal domain. Upon binding to the adaptor proteins,
the initiator caspases dimerize and are thereby
activated, leading to cleavage of a specific site in their
protease domains. Each protease domain is then
rearranged into a large and small subunit. Executioner
caspases are initially formed as inactive dimers. Upon
cleavage at a site in the protease domain by an
initiator caspase, the executioner caspase dimer
undergoes an activating conformational change. It then
cleaves a variety of key proteins, leading to the
controlled death of the cell.
One of the target protein that is cleaved normally holds
a DNA-degrading endonuclease in an inactive form; its
cleavage frees the endonuclease to cut up the DNA in
the cell nucleus.
A key protein in the intrinsic pathway is cytochrome c, a watersoluble component of the mitochondrial electron-transport chain.
When released into the cytosol, it takes on a new function: it binds
to an adaptor protein (Apaf1 apoptotic protease activating factor1), causing it to oligomerize into a wheel-like heptamer called an
apoptosome. The Apaf1 proteins in the apoptosome then recruit
initiator caspase-9 proteins, which are activated by proximity in the
Survival
factors are
extracellular
signal molecules that inhibit apoptosis. Most animal cells require
continuous signaling from other cells to avoid apoptosis, so ensure
that cells survive only when and where they are needed. Nerve cells
are produced in excess in the developing nervous system and then
compete for limited amounts of survival factors that are secreted by
the target cells that they eventually connect to.
Survival factors usually bind to cell-surface receptors, which activate
intracellular signaling pathways that suppress the apoptotic survival
program, often by regulating members of the Bcl2 family. Some
survival factors stimulate the synthesis of anti-apoptotic Bcl2 family
proteins, for example. Many others activate the serine/threonine
protein kinase Akt, which, among many other targets,
phosphorylates and inactivates the pro-apoptotic BH3-only protein
Bad. When not phosphorylated, Bad promotes apoptosis by binding
to and inhibiting Bcl2; once phosphorylated, Bad dissociates, freeing
Bcl2 to suppress apoptosis. Akt also suppresses apoptosis by
phosphorylating and inactivating transcription regulatory proteins
that stimulate the transcriptionof genes encoding proteins that
promote apoptosis. Some survival factors act by phosphorylating
and inactivating anti-IAP proteins, thereby enabling IAP (inhibitors
of apoptosis) proteins to suppress apoptosis.
Decreased apoptosis contributes to many cancers. They may be
treated with drugs that simulate apoptosis small chemicals that
interfere with the function of anti-apoptotic Bcl2 family proteins.
These chemicals bind with high affinity, blocking their function.